Identification of therapeutics against emerging and re-emerging viruses remains a continued priority that is only reinforced by the recent SARS-CoV-2 pandemic. Advances in monoclonal antibody (mAb) isolation, characterization, and production make it a viable option for rapid treatment development. While mAbs are traditionally screened and selected based on potency of neutralization in vitro, it is clear that additional factors contribute to the in vivo efficacy of a mAb beyond viral neutralization. These factors include interactions with Fc receptors (FcRs) and complement that can enhance neutralization, clearance of infected cells, opsonization of virions, and modulation of the innate and adaptive immune response. In this review, we discuss recent studies, primarily using mouse models, that identified a role for Fc-FcγR interactions for optimal antibody-based protection against emerging and re-emerging virus infections.
【저자키워드】 antibodies, emerging viruses, Fc effector functions, 【초록키워드】 Treatment, Efficacy, neutralization, SARS-CoV-2 pandemic, monoclonal antibody, complement, in vitro, virus, infections, Isolation, viral neutralization, Adaptive immune response, Mouse models, in vivo, mAb, Interaction, identification, Factor, modulation, infected cells, advance, virions, clearance, while, ENhance, Fc receptor, selected, include, screened, contribute, 【제목키워드】 protection, Gamma, Requirement,